Once again a drug directed at just one element of insulin resistence namely glucose level without addressing the effect on lipid homeostasis which must be kept to the forefront. Diet is basic to control of both. Carbohydrate intolerance is the metabolic nail in the shoe and that nail must be removed rather than walking about with it and treating the consequences.
Empagliflozin Approved for Type 2 Diabetes — Physician’s First Watch
Empagliflozin Approved for Type 2 Diabetes
By Kelly Young
The FDA has approved empagliflozin (Jardiance) to help patients with type 2 diabetes improve their glycemic control. It is approved for use as a stand-alone or an adjunct treatment.
Empagliflozin is the third sodium glucose co-transporter 2 inhibitor to be FDA approved. It blocks the kidneys' reabsorption of glucose, boosts glucose excretion, and reduces elevated blood glucose levels.
Adverse events associated with empagliflozin include urinary tract infections, female genital infections, and dehydration.